GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Notes Receivable

NeoImmuneTech (XKRX:950220) Notes Receivable : ₩0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Notes Receivable?

NeoImmuneTech's Notes Receivable for the quarter that ended in Dec. 2023 was ₩0.00 Mil.


NeoImmuneTech Notes Receivable Historical Data

The historical data trend for NeoImmuneTech's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Notes Receivable Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeoImmuneTech Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


NeoImmuneTech Notes Receivable Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoImmuneTech (XKRX:950220) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines